James M. Frates Purchases 40,000 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CFO James M. Frates bought 40,000 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was acquired at an average cost of $2.53 per share, for a total transaction of $101,200.00. Following the completion of the purchase, the chief financial officer now directly owns 233,464 shares of the company’s stock, valued at $590,663.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Amylyx Pharmaceuticals Stock Performance

Shares of NASDAQ:AMLX opened at $2.92 on Wednesday. Amylyx Pharmaceuticals, Inc. has a 52-week low of $1.58 and a 52-week high of $19.95. The firm has a market capitalization of $198.58 million, a P/E ratio of -2.73 and a beta of -0.62. The stock has a 50 day moving average price of $2.16 and a 200-day moving average price of $2.61.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.35). Amylyx Pharmaceuticals had a negative net margin of 17.86% and a negative return on equity of 15.51%. The firm had revenue of ($1.02) million for the quarter, compared to analysts’ expectations of $18.83 million. During the same period in the prior year, the business posted $0.31 EPS. On average, equities analysts forecast that Amylyx Pharmaceuticals, Inc. will post -2.27 EPS for the current fiscal year.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Several hedge funds have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC increased its stake in shares of Amylyx Pharmaceuticals by 52,575.9% during the first quarter. Allspring Global Investments Holdings LLC now owns 15,276 shares of the company’s stock valued at $43,000 after purchasing an additional 15,247 shares in the last quarter. Algert Global LLC bought a new stake in shares of Amylyx Pharmaceuticals in the 2nd quarter worth approximately $47,000. CWM LLC grew its stake in shares of Amylyx Pharmaceuticals by 104.2% in the 2nd quarter. CWM LLC now owns 28,643 shares of the company’s stock worth $54,000 after buying an additional 14,613 shares during the last quarter. Quest Partners LLC bought a new position in Amylyx Pharmaceuticals during the 4th quarter valued at approximately $89,000. Finally, SG Americas Securities LLC raised its stake in Amylyx Pharmaceuticals by 113.6% during the second quarter. SG Americas Securities LLC now owns 55,836 shares of the company’s stock valued at $106,000 after buying an additional 29,697 shares during the last quarter. Institutional investors own 95.84% of the company’s stock.

Wall Street Analysts Forecast Growth

AMLX has been the subject of several research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Amylyx Pharmaceuticals in a report on Wednesday, July 10th. The Goldman Sachs Group lifted their price target on shares of Amylyx Pharmaceuticals from $3.00 to $4.00 and gave the company a “neutral” rating in a report on Friday, July 12th. Six investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Amylyx Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $17.60.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.